The impact of altered polyprotein ratios on the assembly and infectivity of Mason-Pfizer monkey virus
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R01 CA027834
NCI NIH HHS - United States
R01 CA027834-28
NCI NIH HHS - United States
R37 CA027834
NCI NIH HHS - United States
CA 27834
NCI NIH HHS - United States
PubMed
19062065
PubMed Central
PMC3779691
DOI
10.1016/j.virol.2008.10.048
PII: S0042-6822(08)00722-8
Knihovny.cz E-zdroje
- MeSH
- AIDS opičí virologie MeSH
- Cercopithecus aethiops MeSH
- COS buňky MeSH
- genové produkty gag genetika MeSH
- genové produkty pol genetika MeSH
- lidé MeSH
- Masonův-Pfizerův opičí virus genetika patogenita MeSH
- messenger RNA genetika MeSH
- posunová mutace MeSH
- proteosyntéza MeSH
- RNA virová genetika MeSH
- transfekce MeSH
- virion genetika patogenita MeSH
- virové proteiny genetika MeSH
- virus Rousova sarkomu genetika MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- genové produkty gag MeSH
- genové produkty pol MeSH
- messenger RNA MeSH
- RNA virová MeSH
- virové proteiny MeSH
Most retroviruses employ a frameshift mechanism during polyprotein synthesis to balance appropriate ratios of structural proteins and enzymes. To investigate the requirements for individual precursors in retrovirus assembly, we modified the polyprotein repertoire of Mason-Pfizer monkey virus (M-PMV) by mutating the frameshift sites to imitate the polyprotein organization of Rous sarcoma virus (Gag-Pro and Gag-Pro-Pol) or Human immunodeficiency virus (Gag and Gag-Pro-Pol). For the "Rous-like" virus, assembly was impaired with no incorporation of Gag-Pro-Pol into particles and for the "HIV-like" virus an altered morphogenesis was observed. A mutant expressing Gag and Gag-Pro polyproteins and lacking Gag-Pro-Pol assembled intracellular particles at a level similar to the wild-type. Gag-Pro-Pol polyprotein alone neither formed immature particles nor processed the precursor. All the mutants were non-infectious except the "HIV-like", which retained fractional infectivity.
Zobrazit více v PubMed
Andreansky M, Hunter E. Phagemid pSIT permits efficient in-vitro mutagenesis and tightly controlled expression in Escherichia coli. BioTechniques. 1994;16:626–630. PubMed
Arad G, Barmeir R, Kotler M. Ribosomal frameshifting at the Gag-Pol junction in avian leukemia sarcoma-virus forms a novel cleavage site. FEBS Lett. 1995;364:1–4. PubMed
Baril M, Dulude D, Steinberg SV, Brakier-Gingras L. The frameshift stimulatory signal of human immunodeficiency virus type 1 group O is a pseudoknot. J Mol Biol. 2003;331:571–583. PubMed PMC
Bauerova-Zabranska H, Stokrova J, Strisovsky K, Hunter E, Ruml T, Pichova I. The RNA binding G-patch domain in retroviral protease is important for infectivity and D-type morphogenesis of Mason-Pfizer monkey virus. J Biol Chem. 2005;280:42106–42112. PubMed
Bradac J, Hunter E. Polypeptides of Mason-Pfizer monkey virus. 1. Synthesis and processing of the gag-gene products. Virology. 1984;138:260–275. PubMed
Chamorro M, Parkin N, Varmus HE. An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger-RNA. Proc Natl Acad Sci USA. 1992;89:713–717. PubMed PMC
Chiu HC, Yao SY, Wang CT. Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in gag-pol are not essential for incorporation of the Pr160(gag-pol) into virus particles. J Virol. 2002;76:3221–3231. PubMed PMC
Choi G, Park S, Choi B, Hong ST, Lee JY, Hunter E, Rhee SS. Identification of a cytoplasmic targeting retention signal in a retroviral Gag polyprotein. J Virol. 1999;73:5431–5437. PubMed PMC
Clarke AR. Cytosolic chaperonins: a question of promiscuity. Mol Cell. 2006;24:165–167. PubMed
Dinman JD, Richter S, Plant EP, Taylor RC, Hammell AB, Rana TM. The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc Natl Acad Sci USA. 2002;99:5331–5336. PubMed PMC
Dulude D, Baril M, Brakier-Gingras L. Characterization of the frameshift stimulatory signal controlling a programmed-1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Res. 2002;30:5094–5102. PubMed PMC
Farabaugh PJ. Programmed translational frameshifting. Microbiol Rev. 1996;60:103–134. PubMed PMC
Farabaugh PJ. Translational frameshifting: implications for the mechanism of translational frame maintenance. Prog Nucleic Acid Res Mol Biol. 2000;64:131–170. PubMed
Felsenstein KM, Goff SP. Expression of the gag-pol fusion protein of Moloney murine leukemia-virus without gag protein does not induce virion formation or proteolytic processing. J Virol. 1988;62:2179–2182. PubMed PMC
Gheysen D, Jacobs E, Deforesta F, Thiriart C, Francotte M, Thines D, Dewilde M. Assembly and release of Hiv-1 precursor Pr55Gag virus-like particles from recombinant baculovirus infected insect cells. Cell. 1989;59:103–112. PubMed
Grinde B, Cameron CE, Leis J, Weber IT, Wlodawer A, Burstein H, Bizub D, Skalka AM. Mutations that alter the activity of the Rous-sarcoma virus protease. J Biol Chem. 1992;267:9481–9490. PubMed
Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol. 1990;64:2653–2659. PubMed PMC
Hong S, Choi G, Park S, Chung AS, Hunter E, Rhee SS. Type D retrovirus gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol. 2001;75:2526–2534. PubMed PMC
Hoshikawa N, Kojima A, Yasuda A, Takayashiki E, Masuko S, Chiba J, Sata T, Kurata T. Role of the gag and pol genes of human-immunodeficiency-virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus — an ultrastructural-study. J Gen Virol. 1991;72:2509–2517. PubMed
Hung M, Patel P, Davis S, Green SR. Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication. J Virol. 1998;72:4819–4824. PubMed PMC
Jacks T, Varmus HE. Expression of the Rous-sarcoma virus pol gene by ribosomal frameshifting. Science. 1985;230:1237–1242. PubMed
Jacks T, Townsley K, Varmus HE, Majors J. 2 efficient ribosomal frameshifting events are required for synthesis of mouse mammary-tumor virus gag-related polyproteins. Proc Natl Acad Sci USA. 1987;84:4298–4302. PubMed PMC
Jacks T, Madhani HD, Masiarz FR, Varmus HE. Signals for ribosomal frameshifting in the Rous-sarcoma virus gag-pol region. Cell. 1988;55:447–458. PubMed PMC
Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B. Overexpression of the Hiv-1 gag-pol polyprotein results in intracellular activation of Hiv-1 protease and inhibition of assembly and budding of virus-like particles. Virology. 1993;193:661–671. PubMed
Klikova M, Rhee SS, Hunter E, Ruml T. Efficient in-vivo and in-vitro assembly of retroviral capsids from gag precursor proteins expressed in bacteria. J Virol. 1995;69:1093–1098. PubMed PMC
Kubota S, Kubota H, Nagata K. Cytosolic chaperonin protects folding intermediates of G ss from aggregation by recognizing hydrophobic ss-strands. Proc Natl Acad Sci USA. 2006;103:8360–8365. PubMed PMC
Nermut MV, Bron P, Thomas D, Rumlova M, Ruml T, Hunter E. Molecular organization of Mason-Pfizer monkey virus capsids assembled from gag polyprotein in Escherichia coli. J Virol. 2002;76:4321–4330. PubMed PMC
Oertle S, Bowles N, Spahr PF. Complementation studies with Rous-sarcoma virus gag and gag-pol polyprotein mutants. J Virol. 1992;66:3873–3878. PubMed PMC
Park JS, Morrow CD. Overexpression of the gag-pol precursor from human-immunodeficiency-virus type-1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol. 1991;65:5111–5117. PubMed PMC
Park J, Morrow CD. The nonmyristylated Pr160Gag-Pol polyprotein of human-immunodeficiency-virus type-1 interacts with Pr55Gag and is incorporated into virus-like particles. J Virol. 1992;66:6304–6313. PubMed PMC
Parker SD, Hunter E. A cell-line-specific defect in the intracellular transport and release of assembled retroviral capsids. J Virol. 2000;74:784–795. PubMed PMC
Parker SD, Hunter E. Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro. Proc Natl Acad Sci. 2001;98:14631–14636. PubMed PMC
Parker SD, Wall JS, Hunter E. Analysis of Mason-Pfizer monkey virus gag particles by scanning transmission electron microscopy. J Virol. 2001;75:9543–9548. PubMed PMC
Ridky TW, BizubBender D, Cameron CE, Weber IT, Wlodawer A, Copeland T, Skalka AM, Leis J. Programming the Rous sarcoma virus protease to cleave new substrate sequences. J Biol Chem. 1996;271:10538–10544. PubMed
Rumlova-Klikova M, Hunter E, Nermut MV, Pichova I, Ruml T. Analysis of Mason-Pfizer monkey virus gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol. 2000;74:8452–8459. PubMed PMC
Sakalian M, Parker SD, Weldon RA, Hunter E. Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol. 1996;70:3706–3715. PubMed PMC
Sfakianos JN, Hunter E. M-PMV capsid transport is mediated by Env/Gag interactions at the pericentriolar recycling endosome. Traffic. 2003;4:671–680. PubMed
Sfakianos JN, LaCasse RA, Hunter E. The M-PMV cytoplasmic targeting-retention signal directs nascent gag polypeptides to a pericentriolar region of the cell. Traffic. 2003;4:660–670. PubMed
Shehu-Xhilaga M, Crowe SM, Mak J. Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol. 2001;75:1834–1841. PubMed PMC
Smith AJ, Srinivasakumar N, Hammarskjold ML, Rekosh D. Requirements for incorporation of Pr160Gag-Pol from human-immunodeficiency-virus type-1 into virus-like particles. J Virol. 1993;67:2266–2275. PubMed PMC
Sommerfelt MA, Petteway SR, Dreyer GB, Hunter E. Effect of retroviral proteinase-inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol. 1992;66:4220–4227. PubMed PMC
Song CS, Hunter E. Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein. J Virol. 2003;77:7779–7785. PubMed PMC
Sonigo P, Barker C, Hunter E, Wainhobson S. Nucleotide-sequence of Mason-Pfizer monkey virus — an immunosuppressive D-type retrovirus. Cell. 1986;45:375–385. PubMed
Stansell E, Tytler E, Walter MR, Hunter E. An early stage of Mason-Pfizer monkey virus budding is regulated by the hydrophobicity of the gag matrix domain core. J Virol. 2004;78:5023–5031. PubMed PMC
Vlach J, Lipov J, Rumlova M, Veverka V, Lang J, Srb P, Knejzlik Z, Pichova I, Hunter E, Hrabal R, Ruml T. D-retrovirus morphogenetic switch driven by the targeting signal accessibility to Tctex-1 of dynein. Proc Natl Acad Sci USA. 2008;105:10565–10570. PubMed PMC
Yoshinaka Y, Katoh I, Copeland TD, Oroszlan S. Murine leukemia-virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci USA. 1985;82:1618–1622. PubMed PMC
Unveiling the DHX15-G-patch interplay in retroviral RNA packaging